NP_001230705.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
56,490 Da
NCBI Official Full Name
centrosomal protein of 57 kDa isoform b
NCBI Official Synonym Full Names
centrosomal protein 57
NCBI Protein Information
centrosomal protein of 57 kDa
UniProt Protein Name
Centrosomal protein of 57 kDa
UniProt Synonym Protein Names
FGF2-interacting protein; Testis-specific protein 57; Translokin
UniProt Synonym Gene Names
UniProt Entry Name
CEP57_HUMAN
NCBI Summary for CEP57
This gene encodes a cytoplasmic protein called Translokin. This protein localizes to the centrosome and has a function in microtubular stabilization. The N-terminal half of this protein is required for its centrosome localization and for its multimerization, and the C-terminal half is required for nucleating, bundling and anchoring microtubules to the centrosomes. This protein specifically interacts with fibroblast growth factor 2 (FGF2), sorting nexin 6, Ran-binding protein M and the kinesins KIF3A and KIF3B, and thus mediates the nuclear translocation and mitogenic activity of the FGF2. It also interacts with cyclin D1 and controls nucleocytoplasmic distribution of the cyclin D1 in quiescent cells. This protein is crucial for maintaining correct chromosomal number during cell division. Mutations in this gene cause mosaic variegated aneuploidy syndrome, a rare autosomal recessive disorder. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]
UniProt Comments for CEP57
CEP57: Centrosomal protein which may be required for microtubule attachment to centrosomes. May act by forming ring- like structures around microtubules. Mediates nuclear translocation and mitogenic activity of the internalized growth factor FGF2. Defects in CEP57 are the cause of mosaic variegated aneuploidy syndrome type 2 (MVA2). MVA2 is a severe developmental disorder characterized by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay, and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor and leukemia reported in several cases. Belongs to the translokin family. 4 isoforms of the human protein are produced by alternative splicing.
Chromosomal Location of Human Ortholog: 11q21
Cellular Component: centrosome; cytoplasm; cytosol; Golgi apparatus; microtubule; microtubule cytoskeleton; nucleoplasm; nucleus
Molecular Function: fibroblast growth factor binding; microtubule binding; protein binding; protein homodimerization activity
Biological Process: fibroblast growth factor receptor signaling pathway; G2/M transition of mitotic cell cycle; mitotic sister chromatid segregation; protein import into nucleus, translocation; spermatid development
Disease: Mosaic Variegated Aneuploidy Syndrome 2
Research Articles on CEP57
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with anti-CEP57 antibody
Diseases associated with anti-CEP57 antibody
Organs/Tissues associated with anti-CEP57 antibody
|